Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
American Journal of Hematology · 2024-10 · 99 (10) · 1870-1876
DOI: 10.1002/ajh.27417 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 20.06.2024. Verfasst von Sylvain Garciaz und 27 weiteren Autor:innen. Beteiligte Einrichtung: Département d'hématologie, Institut Paoli-Calmettes, Université d'Aix-Marseille, INSERM U1068, CNRS, Marseille, France. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Azacitidine, Sulfonamides, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Venetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE‐A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax‐azacitidine due to poor tolerance. Sixty‐two newly diagnosed (ND) AML patients and 22 patients with morphological relapse or refractory AML were included. In the ND cohort ( n = 62), 28 patients stopped venetoclax and azacitidine and 34 patients continued azacitidine monotherapy. With a median follow‐up of 23 months (IQR, 20–32), median overall survival and treatment‐free survival were 44 (IQR, 16‐NR) and 16 (IQR, 8–27) months, respectively. Patients who stopped both treatments and those who continued azacitidine monotherapy had the same outcomes. Negative minimal residual disease was associated with a 2‐year treatment‐free survival of 80%. In the RR cohort ( n = 22), median overall survival and treatment‐free survival were 19 (IQR, 17–31) and 10 (IQR, 5‐NR) months, respectively. Prior number of venetoclax‐azacitidine cycles and IDH mutations were associated with increased overall survival. The only factor significantly impacting treatment‐free survival was the number of prior cycles. This study suggests that patients who discontinued treatment in remission have favorable outcomes supporting the rationale for prospective controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Département d'hématologie, Institut Paoli-Calmettes, Université d'Aix-Marseille, INSERM U1068, CNRS, Marseille, France.
- CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Université de Bordeaux, Bordeaux, France.
- Service d'hématologie, Centre Hospitalo-universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France.
- Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
- Département d'hématologie, Hôpital Cochin, APHP, Paris, France.
ORCID-Profile: Sylvain Garciaz, Sarah Bertoli, David A Sallman, Amine Belhabri, Corentin Orvain, Pierre Peterlin, Sarah Bonnet, Onyee Chan, Jeffrey Lancet, François Vergez, Nicolas Chapuis, Norbert Vey, Christian Récher
Zitieren
APA
Garciaz, S., Dumas, P. Y., Bertoli, S., Sallman, D. A., Decroocq, J., Belhabri, A., Orvain, C., Aspas Requena, G., Simand, C., Laribi, K., Carré, M., Santagostino, A., Himberlin, C., Peterlin, P., Bonnet, S., Chan, O., Lancet, J., Komrokji, R., Vergez, F., …, & Récher, C. (2024). Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. American Journal of Hematology, 99(10), 1870-1876. https://doi.org/10.1002/ajh.27417
Vancouver
Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, et al. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. American Journal of Hematology. 2024;99(10):1870-1876. doi:10.1002/ajh.27417
BibTeX
@article{Garciaz2024,
author = {Garciaz, Sylvain and Dumas, Pierre-Yves and Bertoli, Sarah and Sallman, David A and Decroocq, Justine and Belhabri, Amine and Orvain, Corentin and Aspas Requena, Gaspar and Simand, Celestine and Laribi, Kamel and Carré, Martin and Santagostino, Alberto and Himberlin, Chantal and Peterlin, Pierre and Bonnet, Sarah and Chan, Onyee and Lancet, Jeffrey and Komrokji, Rami and Vergez, François and Chapuis, Nicolas and Raskovalova, Tatiana and Plesa, Adriana and Lhoumeau, Anne-Catherine and Mineur, Ariane and Hospital, Marie Anne and Pigneux, Arnaud and Vey, Norbert and Récher, Christian},
title = {Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {10},
pages = {1870--1876},
doi = {10.1002/ajh.27417}
}
EUVIMED